Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
03/2009
03/19/2009WO2009033763A1 Nafarelin and carboxymethyl-phe-leu as therapeutic agents
03/19/2009WO2009033762A2 Use of endothelin-3 as a therapeutic agent
03/19/2009WO2009033761A2 Use of a fragment of hcv nucleo protein, alone or together with endothelin-3, as a therapeutic agent
03/19/2009WO2009033760A2 Use of fibronectin fragment (196-203 ) as a therapeutic agent
03/19/2009WO2009033759A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033758A2 Use of the peptide phpfhffvyk as therapeutic agent
03/19/2009WO2009033757A2 Use of mage-3 antigen (271-279) as a therapeutic agent
03/19/2009WO2009033756A2 Use of oxyntomodulin alone or in combination with melanotropin potentiating factor as a therapeutic agent
03/19/2009WO2009033755A2 Use of l-carnosine as a therapeutic agent
03/19/2009WO2009033754A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033751A2 Use of leu-enkephalin as a therapeutic agent
03/19/2009WO2009033750A2 Use of phm-27 alone or in combination with leu-enkephalin as a therapeutic agent
03/19/2009WO2009033749A2 Use of thymopentin as a therapeutic agent
03/19/2009WO2009033748A2 Use of osteostatin, alone or in combination with thymopentin, as a therapeutic agent
03/19/2009WO2009033747A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033746A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033745A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033744A1 Use of urodilatin as a therapeutic agent
03/19/2009WO2009033741A2 Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s)
03/19/2009WO2009033740A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033739A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033738A2 Use of glucagon (1-29) alone or in combination with neuropeptide w30 as a therapeutic agent
03/19/2009WO2009033736A2 Use of met-enkephalin as a therapeutic agent
03/19/2009WO2009033735A2 Use of melanin concentrating hormone and met-enkephalin as therapeutic agents
03/19/2009WO2009033734A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033733A2 Use of apeptide as a therapeutic agent
03/19/2009WO2009033732A2 Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent
03/19/2009WO2009033731A2 Use of a laminin peptide as a therapeutic agent
03/19/2009WO2009033730A2 Peptide gxgrgdspca as a therapeutic agent
03/19/2009WO2009033729A2 Therapeutic uses of gastrin- 1 and g- pen-grgdspca
03/19/2009WO2009033726A2 Use of cart (55-102), optionally in combination with tuftsin, as a therapeutic agent
03/19/2009WO2009033725A1 Use of human neuropeptide as a therapeutic agent
03/19/2009WO2009033724A1 Use of c-type natriuretic peptide, alone or incombination with neuropeptide af, as a therapeutic agent
03/19/2009WO2009033723A2 Use of aip2 as a therapeutic agent
03/19/2009WO2009033722A2 Use of a octreotide as a therapeutic agent
03/19/2009WO2009033721A2 Use of salusin beta alone or in combination with octreotide as a therapeutic agent
03/19/2009WO2009033720A1 Mastoparan for the treatment of diseases
03/19/2009WO2009033719A2 Use of a deslorelin and mastoparan as a therapeutic agent
03/19/2009WO2009033718A2 Use of anti -inflammatory peptide 1 as a therapeutic agent
03/19/2009WO2009033717A2 Use of gonadorelin as a therapeutic agent
03/19/2009WO2009033714A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033712A2 Use of melanotan ii as a therapeutic agent
03/19/2009WO2009033711A2 Use of glp-1 as a therapeutic agent
03/19/2009WO2009033710A1 Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine
03/19/2009WO2009033707A2 Use of retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections
03/19/2009WO2009033701A1 Use of urodilatin as a therapeutic agent
03/19/2009WO2009033700A1 Use of secretin and optionally urodilatin as therapeutic agents
03/19/2009WO2009033696A1 Use of a peptide pyx-1 as a therapeutic agent
03/19/2009WO2009033692A2 Use of the peptides fibrinopeptide a and pyx-i as a therapeutic agents
03/19/2009WO2009033690A1 Bfgf (119-126) for therapeutic applications
03/19/2009WO2009033687A1 Spantide ii and bfgf (119-126) for therapeutic applications
03/19/2009WO2009033684A1 Minigastrin as a therapeutic agent
03/19/2009WO2009033681A2 Cyclo-argd as a therapeutic agent
03/19/2009WO2009033680A2 Galanin-like peptide alone or in combination with cyclo-argd as a therapeutic agent
03/19/2009WO2009033678A2 Use of a tuftsin as a therapeutic agent
03/19/2009WO2009033669A2 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent
03/19/2009WO2009033668A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033667A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033666A2 Use of parathyroid hormone ( 1-34 ) as anti-hiv agent
03/19/2009WO2009033665A2 Use of a rgd-peptide and/or parathyroid hormone (1-34 ) as anti-hiv agent
03/19/2009WO2009033664A1 Use of delta-endorphin as a therapeutic agent
03/19/2009WO2009033663A1 Use of fertirelin and delta-endorphin as therapeutic agents
03/19/2009WO2009033661A2 Use of rgdspasskp and optionally angiotensin ii as therapeutic agents in the treatment of eg s. pneumoniae infections
03/19/2009WO2009033660A2 Use of octreotide as a therapeutic agent
03/19/2009WO2009033659A1 Hcv protease inhibitor and octreotide as therapeutic agents
03/19/2009WO2009033658A1 (d-leu7 ) -histrelin as a therapeutic agent
03/19/2009WO2009033657A2 Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents
03/19/2009WO2009033656A2 Use of follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumoniae infection
03/19/2009WO2009033561A1 Substituted 6-phenylnicotinic acids and the use thereof
03/19/2009WO2009033373A1 Use of neuregulin for organ preservation
03/19/2009WO2009033305A1 5-ht3 receptor antagonists for the teatment of myocardial infarction, thrombosis and atherosclerosis
03/19/2009WO2009015812A3 Prodrugs of 2-amino-6- ( { [2- (4-chlorphenyl) -1, 3-thiaz0l-4-yl] methyl}thio) -4- [4- ( 2 -hydroxyethoxy) phenyl] pyridin-3, 5-dicarbonitrile
03/19/2009WO2009007348A3 Use of antagonists of g protein coupled receptors (gpcrs) for treating diseases caused by agonistic autoantibodies activated gpcrs
03/19/2009WO2009006567A3 Pyrimidyl cyclopentanes as akt protein kinase inhibitors
03/19/2009WO2009005646A3 Substituted piperazines as cb1 antagonists
03/19/2009WO2009000296A3 Tpp ii inhibitors for use in the treatment of autoimmune and inflammatory diseases and transplant rejection
03/19/2009WO2008152226A3 Homogeneous and stable composition rich in oleaginous substances based on a milk product, method for the preparation thereof and uses thereof
03/19/2009WO2008104306A3 Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
03/19/2009WO2008063157A3 A nanoparticle-based anticoagulant
03/19/2009WO2008039139A8 Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine derivatives and their use in therapy
03/19/2009WO2008039138A8 Novel 5, 7-disubstituted [1, 3 ] thiazolo [4, 5-d] pyrimidin-2 (3h)-one derivatives and their use in therapy
03/19/2009US20090077681 Methods for Diagnosing and Treating Heart Disease
03/19/2009US20090076276 such as (R)-3-(3-hydroxypyrrolidin-1-yl)-N-methyl-N-methoxypropanamide; poly(ADP-ribose)polymerase inhibitors
03/19/2009US20090076264 Deuterium-enriched rivaroxaban
03/19/2009US20090076151 Method for stimulating weight loss and/or for lowering triglycerides in patients
03/19/2009US20090076140 Pharmaceutical compositions containing sulphonic acid derivatives
03/19/2009US20090076137 Deuterium-enriched dronedarone
03/19/2009US20090076134 Deuterium-enriched simvastatin
03/19/2009US20090076126 Deuterium-enriched enalapril
03/19/2009US20090076120 Crystal of Aminopyrrolidine Derivative and Production Method Thereof
03/19/2009US20090076117 Deuterium-enriched laropiprant
03/19/2009US20090076116 Deuterium-enriched carvediolo
03/19/2009US20090076106 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels
03/19/2009US20090076105 Preventive or therapeutic agent for cerebral ischemic injury or cerebral ischemia reperfusion in stroke
03/19/2009US20090076104 Deuterium-enriched losartan
03/19/2009US20090076095 Deuterium-enriched nicorandil
03/19/2009US20090076070 Hetero compound
03/19/2009US20090076069 Deuterium-enriched apixaban
03/19/2009US20090076068 Imidazopyridin-2-one derivatives as inhibitors of lipases and phospholipases
03/19/2009US20090076062 Organic Compounds
1 ... 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 ... 1595